Preview

Вопросы современной педиатрии

Расширенный поиск

РЕВМАТИЧЕСКИЕ ЗАБОЛЕВАНИЯ И ЭНДОТЕЛИАЛЬНАЯ ФУНКЦИЯ

https://doi.org/10.15690/vsp.v17i2.1878

Полный текст:

Аннотация

В обзоре проанализирована роль хронических воспалительных заболеваний в индукции эндотелиальной дисфункции как фактора акселерации атеросклеротических изменений в сердечно-сосудистой системе. Обсуждается значение неинвазивных методов оценки дисфункции эндотелия для выявления доклинических атеросклеротических изменений у детей и подростков с ревматическими заболеваниями. Постулируется, что выявление ранних признаков эндотелиальной дисфункции у детей и подростков с ревматическими заболеваниями наряду с традиционными факторами риска должно стать составной частью стратегии профилактики неблагоприятных сердечно-сосудистых событий в последующие возрастные периоды.

Об авторах

В. Л. Марчук
Омский государственный медицинский университет
Россия

Марчук Варвара Леонидовна - ассистент кафедры педиатрии ОмГМА.

644007, Омск, ул. Орджоникидзе, д. 58,  тел.: +7 (3812) 23-01-84



Н. В. Соботюк
Омский государственный медицинский университет
Россия


С. В. Бочанцев
Омский государственный медицинский университет
Россия


Список литературы

1. www.who.int [Internet]. WHO. Cardiovascular diseases (CVDs) [cited 2018 Mar 12]. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/.

2. Townsend N, Wilson L, Bhatnagar P, et al. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232–3245. doi: 10.1093/eurheartj/ehw334.

3. Collaborators GBDRF. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–1724. doi: 10.1016/S0140-6736(16)31679-8.

4. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008. doi: 10.1016/s0140-6736(13)61752-3.

5. Laitinen TT, Pahkala K, Magnussen CG, et al. Lifetime measures of ideal cardiovascular health and their association with subclinical atherosclerosis: The Cardiovascular Risk in Young Finns Study. Int J Cardiol. 2015;185:186–191. doi: 10.1016/j.ijcard.2015.03.051.

6. Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A metaanalysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697. doi: 10.1002/art.24092.

7. del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737–2745.

8. Pieringer H, Pichler M. Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM. 2010;104(1):13–26. doi: 10.1093/qjmed/hcq203.

9. Brady SR, de Courten B, Reid CM, et al. The role of traditional cardiovascular risk factors among patients with rheumatoid arthritis. J Rheumatol. 2009;36(1):34–40. doi: 10.3899/jrheum.080404.

10. Chung CP, Giles JT, Petri M, et al. Prevalence of traditional modifiable cardiovascular risk factors in patients with rheumatoid arthritis: comparison with control subjects from the multi-ethnic study of atherosclerosis. Semin Arthritis Rheum. 2012;41(4):535–544. doi: 10.1016/j.semarthrit.2011.07.004.

11. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481. doi: 10.1016/s0140-6736(05)70270-1.

12. Solomon DH, Avorn J, Sturmer T, et al. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006;54(5):1378–1389. doi: 10.1002/art.21887.

13. Pietri P, Vyssoulis G, Vlachopoulos C, et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens. 2006;24(11):2231–2238. doi: 10.1097/01.hjh.0000249701.49854.21.

14. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524–1529. doi: 10.1136/annrheumdis-2011-200726.

15. Solomon DH, Reed GW, Kremer JM, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449–1455. doi: 10.1002/art.39098.

16. Rongen GA, van Ingen I, Kok M, et al. Vasodilator function worsens after cessation of tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis only if a flare occurs. Clin Rheumatol. 2018;37(4):909–916. doi: 10.1007/s10067-017-3961-6.

17. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–1143. doi: 10.1161/hc0902.104353.

18. Ozbalkan Z, Efe C, Cesur M, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis. 2010;212(2):377–382. doi: 10.1016/j.atherosclerosis.2010.03.035.

19. van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis. 2009;68(9):1395–1400. doi: 10.1136/ard.2008.094151.

20. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331. doi: 10.1136/ard.2009.113696.

21. Shoenfeld Y, Gerli R, Doria A, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337–3347. doi: 10.1161/CIRCULATIONAHA.104.507996.

22. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–2738. doi: 10.1161/CIRCULATIONAHA.106.179568.

23. Myasoedova E, Gabriel SE, Matteson EL, et al. Decreased cardiovascular mortality in patients with incident rheumatoid arthritis (RA) in recent years: dawn of a new era in cardiovascular disease in RA? J Rheumatol. 2017;44(6):732–739. doi: 10.3899/jrheum.161154.

24. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370. doi: 10.1016/j.amjcard.2011.06.054.

25. Souto A, Salgado E, Maneiro JR, et al. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2015;67(1):117–127. doi: 10.1002/art.38894.

26. Ferrante A, Giardina AR, Ciccia F, et al. Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intimamedia thickness in female patients with active rheumatoid arthritis. Rheumatol Int. 2009;30(2):193–198. doi: 10.1007/s00296-009-0935-2.

27. del Rincon I, Polak JF, O’Leary DH, et al. Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis. Ann Rheum Dis. 2015;74(6):1118–1123. doi: 10.1136/annrheumdis-2013-205058.

28. Holman RL. Atherosclerosis — a pediatric nutrition problem? Am J Clin Nutr. 1961;9:565–569. doi: 10.1093/ajcn/9.5.565.

29. Berenson GS, Wattigney WA, Tracy RE, et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). Am J Cardiol. 1992;70(9):851–858. doi: 10.1016/0002-9149(92)90726-F.

30. Wissler RW, Strong JP. Risk factors and progression of atherosclerosis in youth. PDAY Research Group. Pathological Determinants of Atherosclerosis in Youth. Am J Pathol. 1998;153(4):1023–1033. doi: 10.1016/S0002-9440(10)65647-7.

31. McGill HC Jr, McMahan CA, Herderick EE, et al. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr. 2000;72(5 Suppl):1307S–1315S. doi: 10.1093/ajcn/72.5.1307s.

32. McGill HC Jr, McMahan CA, Gidding SS. Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation. 2008;117(9):1216–1227. doi: 10.1161/CIRCULATIONAHA.107.717033.

33. Newman WP 3rd, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med. 1986;314(3):138–144. doi: 10.1056/NEJM198601163140302.

34. Wissler RW. USA Multicenter Study of the pathobiology of athero sclerosis in youth. Ann N Y Acad Sci. 1991;623(1):26–39. doi: 10.1111/j.1749-6632.1991.tb43716.x.

35. Lauer RM, Connor WE, Leaverton PE, et al. Coronary heart disease risk factors in school children: the Muscatine study. J Pediatr. 1975;86(5):697–706.

36. Akerblom HK, Viikari J, Uhari M, et al. Atherosclerosis precursors in Finnish children and adolescents. I. General description of the cross-sectional study of 1980, and an account of the children’s and families’ state of health. Acta Paediatr Scand Suppl. 1985;318:49–63. doi: 10.1111/j.1651-2227.1985.tb10082.x.

37. Dwyer T, Sun C, Magnussen CG, et al. Cohort Profile: the international childhood cardiovascular cohort (i3C) consortium. Int J Epidemiol. 2013;42(1):86–96. doi: 10.1093/ije/dys004.

38. Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation. 2013;128(3):217–224. doi: 10.1161/CIRCULATIONAHA.113.001614.

39. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3’:5’-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977;74(8):3203–3207. doi: 10.1073/pnas.74.8.3203.

40. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–376. doi: 10.1038/288373a0.

41. Ignarro LJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987;84(24):9265–9269. doi: 10.1073/pnas.84.24.9265.

42. Flammer AJ, Luscher TF. Human endothelial dysfunction: EDRFs. Pflugers Arch. 2010;459(6):1005–1013. doi: 10.1007/s00424-010-0822-4.

43. Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: EDCFs. Pflugers Arch. 2010;459(6):1015–1023. doi: 10.1007/s00424-009-0783-7.

44. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9(10):1057–1069. doi: 10.7150/ijbs.7502.

45. Feletou M, Kohler R, Vanhoutte PM. Nitric oxide: orchestrator of endothelium-dependent responses. Ann Med. 2012;44(7):694–716. doi: 10.3109/07853890.2011.585658.

46. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res. 2001;88(8):756–762. doi: 10.1161/hh0801.089861.

47. Hossain M, Qadri SM, Liu L. Inhibition of nitric oxide synthesis enhances leuko-cyte rolling and adhesion in human microvasculature. J Inflamm (Lond). 2012;9(1):28. doi: 10.1186/1476-9255-9-28.

48. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9(11):1370–1376. doi: 10.1038/nm948.

49. Vecchione C, Carnevale D, Di Pardo A, et al. Pressureinduced vascular oxidative stress is mediated through activation of integrinlinked kinase 1/betaPIX/Rac-1 pathway. Hypertension. 2009;54(5):1028–1034. doi: 10.1161/HYPERTENSIONAHA.109.136572.

50. Walsh T, Donnelly T, Lyons D. Impaired endothelial nitric oxide bioavailability: a common link between aging, hypertension, and atherogenesis? J Am Geriatr Soc. 2009;57(1):140–145. doi: 10.1111/j.1532-5415.2008.02051.x.

51. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med. 2005;7(7):1–24. doi: 10.1017/S1462399405009154.

52. Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009;48(1):11–22. doi: 10.1093/rheumatology/ken395.

53. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–175. doi: 10.1161/01.ATV.0000051384.43104.FC.

54. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332(8):481–487. doi: 10.1056/NEJM199502233320801.

55. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation. 1996;94(3):258–265. doi: 10.1161/01.cir.94.3.258.

56. Ting HH, Timimi FK, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation. 1997;95(12):2617–2622. doi: 10.1161/01.CIR.95.12.2617.

57. Hambrecht R, Wolf A, Gielen S, et al. Effects of exercise on coronary endothelial function in patients with coronary artery disease. N Engl J Med. 2000;342(7):454–460. doi: 10.1056/NEJM200002173420702.

58. Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis. 2012;224(2):309–317. doi: 10.1016/j.atherosclerosis.2012.05.013.

59. Ku IA, Imboden JB, Hsue PY, Ganz P. Rheumatoid arthritis: a model of systemic inflammation driving atherosclerosis. Circ J. 2009;73(6):977–985. doi: 10.1253/circj.cj-09-0274.

60. Toms TE, Panoulas VF, Douglas KM, et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial under-treatment of lipid-associated cardiovascular risk? Ann Rheum Dis. 2010;69(4):683–688. doi: 10.1136/ard.2009.115717.

61. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol. 2009;28(4):439–444. doi: 10.1007/s10067-008-1073-z.

62. Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. The role of exercise in the management of rheumatoid arthritis. Expert Rev Clin Immunol. 2015;11(10):1121–1130. doi: 10.1586/1744666X.2015.1067606.

63. Toms TE, Panoulas VF, John H, et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an antiinflammatory effect? A cross sectional study. Arthritis Res Ther. 2009;11(4):R110. doi: 10.1186/ar2765.

64. Del Rincon I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 2005;52(11):3413–3423. doi: 10.1002/art.21397.

65. Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48–54. doi: 10.1136/annrheumdis-2017-211735.

66. Попкова Т.В., Новикова Д.С., Писарев В.В., и др. Факторы риска кардиоваскулярных заболеваний при ревматоидном aртрите // Научно-практическая ревматология. — 2009. — Т. 47. — № 3 — С. 4–11. doi: 10.14412/1995-4484-2009-1306.

67. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death — a Danish nationwide cohort study. PLOS One. 2013;8(2):e56944. doi: 10.1371/journal.pone.0056944.

68. Clapp BR, Hingorani AD, Kharbanda RK, et al. Inflammationinduced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc Res. 2004;64(1):172–178. doi: 10.1016/j.cardiores.2004.06.020.

69. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardio-vascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58(8):2268–2274. doi: 10.1002/art.23650.

70. Barbhaiya M, Solomon DH. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues. Curr Opin Rheumatol. 2013;25(3):317–324. doi: 10.1097/BOR.0b013e32835fd7f8.

71. Ridker РМ, Everett ВМ, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131. doi: 10.1056/NEJMoa1707914.

72. Волков А.В., Линева О.Г., Кузикянц K.K., и др. Влияние терапии ритуксимабом на функцию эндотелия и другие маркеры атеросклероза у пациентов с активным ревматоидным артритом // Научно-практическая ревматология. — 2010. — Т. 48. — № 6 — С. 31–36. doi: 10.14412/1995-4484-2010-820.

73. Насонов Е.Л., Попкова Т.В. Противовоспалительная терапия атеросклероза — вклад и уроки ревматологии // Научно-практическая ревматология. — 2017. — Т. 55. — № 5 — С. 465–473. doi: 10.14412/1995-4484-2017-465-473.

74. Smith EM, Foster HE, Beresford MW. Adding to complexi ty: comorbidity in paediatric rheumatic disease. Rheumatology (Oxford). 2013;52(1):22–33. doi: 10.1093/rheumatology/kes256.

75. Nordal E, Zak M, Aalto K, et al. Ongoing disease activity and changing categories in a long-term nordic cohort study of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(9):2809–2818. doi: 10.1002/art.30426.

76. Selvaag AM, Aulie HA, Lilleby V, Flato B. Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(1):190–195. doi: 10.1136/annrheumdis-2014-206034.

77. Bohr A, Fuhlbrigge RC, Pedersen FK, et al. Premature subclinical atherosclerosis in children and young adults with juvenile idiopathic arthritis. A review considering preventive measures. Pediatr Rheumatol Online J. 2016;14(1):3. doi: 10.1186/s12969-015-0061-5.

78. Coulson EJ, Ng WF, Goff I, Foster HЕ. Cardiovascular risk in juvenile idiopathic arthritis. Rheumatology (Oxford). 2013;52(7):1163–1171. doi: 10.1093/rheumatology/ket106.

79. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the BogalusaHeart Study. JAMA. 2003;290(17):2271–2276. doi: 10.1001/jama.290.17.2271.

80. Krebs A, Schmidt-Trucksass A, Alt J, et al. Synergistic effect of elevated systolic blood pressure and hypercholesterolaemia on carotid intima-media thickness in children and adolescents. Pediatr Cardiol. 2009;30(8):1131–1136. doi: 10.1007/s00246-009-9510-6.

81. Magnussen C, Smith K, Juonala M. What the long term cohort studies that began in childhood have taught us about the origins of coronary heart disease. Curr Cardiovasc Risk Rep. 2014;8(2):1–10. doi: 10.1007/s12170-014-0373-x.

82. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315(17):1046–1051. doi: 10.1056/NEJM198610233151702.

83. Flammer AJ, Anderson Т, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126(6):753–767. doi: 10.1161/CIRCULATIONAHA.112.093245.

84. Lorenz MW, Markus HS, Bots ML, et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–467. doi: 10.1161/CIRCULATIONAHA.106.628875.

85. Green DJ, Dawson EA, Groenewoud HM, et al. Is flow-mediated dilation nitric oxide mediated?: a meta-analysis. Hypertension. 2014;63(2):376–382. doi: 10.1161/HYPERTENSIONAHA.113.02044.

86. Shechter M, Shechter A, Koren-Morag N, et al. Usefulness of brachial artery flow-mediated dilation to predict long-term cardiovascular events in subjects without heart disease. Am J Cardiol. 2014;113(1):162–167. doi: 10.1016/j.amjcard.2013.08.051.

87. de Groot L, Posthumus MD, Kallenberg CG, Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest. 2010;40(9):835–842. doi: 10.1111/j.1365-2362.2010.02333.x.

88. Green DJ, Jones H, Thijssen D, et al. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57(3):363–369. doi: 10.1161/HYPERTENSIONAHA.110.167015.

89. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55(13):1318–1327. doi: 10.1016/j.jacc.2009.10.061.

90. Satija M, Yadav TP, Sachdev N, et al. Endothelial function, arterial wall mechanics and intima media thickness in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2014;32(3):432–439.

91. Shah PK. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we? J Am Coll Cardiol. 2010;56(2):98–105. doi: 10.1016/j.jacc.2009.09.081.

92. Ilisson J, Zagura M, Zilmer K, et al. Increased carotid artery intima-media thickness and myeloperoxidase level in children with newly diagnosed juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17:180. doi: 10.1186/s13075-015-0699-x.

93. Aulie HA, Selvaag AM, Gunther A, et al. Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2014;74(8):1515–1521. doi:10.1136/annrheumdis-2013-204804.

94. Breda L, Di Marzio D, Giannini C, et al. Relationship between inflammatory markers, oxidant-antioxidant status and intima-media thickness in prepubertal children with juvenile idiopathic arthritis. Clin Res Cardiol. 2013;102(1):63–71. doi: 10.1007/s00392-012-0496-3.

95. Urbina EM, Williams RV, Alpert BS, et al. Noninvasive as sessment of subclinical athesclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American heart association. Hyperten sion. 2009;54(5):919–950. doi: 10.1161/HYPERTENSIONAHA.109.192639.

96. Schieir O, Tosevski C, Glazier RH, et al. Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis. Ann Rheum Dis. 2017;76(8):1396–1404. doi: 10.1136/annrheumdis-2016-210275.


Для цитирования:


Марчук В.Л., Соботюк Н.В., Бочанцев С.В. РЕВМАТИЧЕСКИЕ ЗАБОЛЕВАНИЯ И ЭНДОТЕЛИАЛЬНАЯ ФУНКЦИЯ. Вопросы современной педиатрии. 2018;17(2):126-132. https://doi.org/10.15690/vsp.v17i2.1878

For citation:


Мarchuk V.L., Sobotyuk N.V., Bochantsev S.V. RHEUMATIC DISEASES AND ENDOTHELIAL FUNCTION. Current Pediatrics. 2018;17(2):126-132. (In Russ.) https://doi.org/10.15690/vsp.v17i2.1878

Просмотров: 589


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)